SCHEMBL12038323

SCHEMBL12038323

CC(=O)OCOc1cc2oc(=O)c(C(=O)ON3C(=O)CCC3=O)cc2cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 9/20 0.38
▸ KDM4E B2RXH2 5/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ CA12 O43570 3/20 0.38
▸ CA2 P00918 3/20 0.38
▸ CA3 P07451 3/20 0.38
▸ CA6 P23280 3/20 0.38
▸ CA7 P43166 3/20 0.38
▸ CA9 Q16790 3/20 0.38
▸ CA14 Q9ULX7 3/20 0.38
▸ GLA P06280 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ CA4 P22748 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MAOA P21397 5/20 0.37
▸ MIF P14174 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12038321 0.88 GAPDH (0.39) MAOBKDM4EALDH1A1CA12CA2
SCHEMBL12038303 0.88 MAOB (0.40) MAOBKDM4EALDH1A1CA12CA2
SCHEMBL12038348 0.83 MAOB (0.35) MAOBKDM4EALDH1A1CA12CA2
SCHEMBL12038332 0.82 MAOB (0.34) MAOBKDM4EALDH1A1CA12CA2
SCHEMBL31114267 0.80 GPR35 (0.44) MAOBKDM4EALDH1A1CA12CA2
SCHEMBL12038366 0.78 MAOB (0.32) MAOBKDM4EALDH1A1HPGDHSD17B10
SCHEMBL12038288 0.78 KDM4E (0.49) MAOBKDM4EALDH1A1CA12CA9
SCHEMBL12038354 0.77 MAPT (0.33) MAOBMAPTMAOA
SCHEMBL12038296 0.77 MAOB (0.37) MAOBKDM4EALDH1A1CA12CA2
SCHEMBL12038297 0.74 MAOB (0.39) MAOBKDM4EALDH1A1CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318953-B2 Reactive coumarin derivatives and their use in cellular analyses AAT BIOQUEST, INC. (US) 2012-11-27 — — US disclosed
US-8318953-B2 Reactive coumarin derivatives and their use in cellular analyses AAT BIOQUEST, INC. (US) 2012-11-27 — — US disclosed
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES AAT BIOQUEST, INC. (US) 2011-12-29 — — US disclosed
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES AAT BIOQUEST, INC. (US) 2011-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES CYP3A7, XPO7, HCCS MAOB 3197/4885KDM4E 4529/4885ALDH1A1 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback